Von Willebrand Factor Antigen in Blood Plasma of Patients With Urinary Bladder Carcinoma

Ziętek, Z; Iwan-Ziętek, I; Paczulski, Ryszard; Kotschy, M; Wolski, Zbigniew

doi:10.1016/0049-3848(96)00149-1

Cited by 36 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients with GBM in our study had supraphysiological VWF:Ag levels and the higher was the VWF level the shorter was the survival rendering VWF:Ag levels a putative prognostic factor. Such a prognostic role for VWF has been shown in patients with other type of cancer, being high VWF levels associated with disease stage, 33, 34, 35, 36, 37, presence of metastases and/or lymph node status 33, 34, 36, 37, tumor size and residual disease after surgery 35. All in all, this study showed a significantly reduced survival in patients with GBMs and preoperative high levels of VWF:Ag in plasma irrespective of age.…”

Section: Discussionmentioning

confidence: 77%

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

et al. 2016

View full text Add to dashboard Cite

Circulating biomarker for malignant gliomas could improve both differential diagnosis and clinical management of brain tumor patients. Among all gliomas, glioblastoma (GBM) is considered the most hypervascularized tumor with activation of multiple proangiogenic signaling pathways that enhance tumor growth. To investigate whether preoperative antigen plasma level of von Willebrand Factor (VWF:Ag) might be possible marker for GBM onset, progression, and prognosis, we retrospectively examined 57 patients with histological diagnosis for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, enrolled as controls. Blood samples were collected from all the patients before tumor resection. Plasma von Willebrand Factor (VWF):Ag levels were determined by using a latex particle‐enhanced immunoturbidimetric assay. The median levels of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) (183 vs. 133 IU/dL, P = 0.01). The cumulative 1‐year survival was significantly shorter in patients with VWF:Ag levels >200 IU/dL than in those with levels <200 IU/dL and increased VWF levels were associated with a threefold higher risk of death in GBM patients. Our data suggest that VWF:Ag could be a circulating biomarker of disease malignancy, that could be considered, in association with other genetic and epigenetic factors, currently available in the GBM management. Future studies should investigate whether plasma VWF:Ag levels could also be used to monitor therapeutic effects and whether it may have a prognostic value.

show abstract

Section: Discussionmentioning

confidence: 77%

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Notably, the levels of VWF were comparable in patients in presence or absence of HCC. It has been suggested that VWF plasma levels may be of prognostic significance in patients with solid tumors [46][47][48], but the prognostic significance of VWF in HCC is absent, perhaps because of the effects of the underlying cirrhotic disease on VWF levels.…”

Section: Discussionmentioning

confidence: 99%

No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma

Alkozai¹,

Porte²,

Adelmeijer³

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

“…Increased plasma levels of VWF antigen have been observed in patients with hematological and non‐hematological malignancies, e.g. acute lymphoblastic leukemia, colorectal cancer, bladder cancer, and ovarian cancer . Higher levels have been found to correlate with cancer stage and VTE occurrence in cancer patients .…”

Section: Discussionmentioning

confidence: 99%

Coagulation and inflammation in long‐term cancer survivors: results from the adult population

Panova‐Noeva

Schulz

Arnold

et al. 2018

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background The advances in cancer treatment and detection of early cancer have resulted in a steady increase in the number of of cancer survivors over the years. However, because of the long-term toxic effects of chemotherapy and radiotherapy, the incidence of cardiovascular disease (CVD) is increasing in survivors. Objectives To investigate traditional cardiovascular risk factors (CVRFs), inflammation and the coagulation profile in long-term cancer survivors (cancer diagnosis ≥ 5 years) from a large adult population-based study sample. Methods The presence of cardiovascular risk factors (CVRFs) and laboratory markers were compared in individuals with (n = 723) and without (n = 13626) a long-term history of cancer from the Gutenberg Health Study. Data on coagulation factors, D-dimer and von Willebrand factor (VWF) activity were available for 4974 individuals (n = 244 cancer survivors). Results In multivariable regression models, a history of cancer was, independently of CVRFs and CVD, associated with higher fibrinogen levels (β 6.99, 95% confidence interval [CI] 1.16-12.8), VWF activity (β 5.08, 95% CI 0.02-10.1), and antithrombin activity (β 1.85, 95% CI 0.44-3.27). Cancer survivors with CVD showed notably higher VWF activity than individuals with CVD without a history of cancer, with a difference in the means of 23.0 (7.9-38.1). Multivariate Cox regression analysis, adjusted for CVRFs, confirmed that a long-term history of cancer is associated with a 72% higher mortality. Increased mortality in cancer survivors was dependent on fibrinogen level and VWF activity level. Conclusion Cancer survivors showed a worse inflammation and coagulation profile than individuals without a history of cancer. Overall mortality in long-term cancer survivors was increased independently of traditional CVRFs. These results underline the need to further investigate plasma biomarkers as complementary cardiovascular risk predictors in cancer survivors.

show abstract

Von Willebrand Factor Antigen in Blood Plasma of Patients With Urinary Bladder Carcinoma

Cited by 36 publications

References 13 publications

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma

Coagulation and inflammation in long‐term cancer survivors: results from the adult population

Contact Info

Product

Resources

About